Endovascular Ablation of the Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction
Authors:
- 1 December 2024
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 9 (12) , 1143-1153
Abstract
Importance: Greater splanchnic nerve ablation may improve hemodynamics in patients with heart failure and preserved ejection fraction (HFpEF).Objective: To explore the feasibility and safety of endovascular right-sided splanchnic nerve ablation for volume management (SAVM).Design, Setting, and Participants: This was a phase 2, double-blind, 1:1, sham-controlled, multicenter, randomized clinical trial conducted at 14 centers in the US and 1 center in the Republic of Georgia. Patients with HFpEF, left ventricular ejection fraction of 40% or greater, and invasively measured peak exercise pulmonary capillary wedge pressure (PCWP) of 25 mm Hg or greater were included. Study data were analyzed from May 2023 to June 2024.Intervention: SAVM vs sham control procedure.Main Outcomes and Measures: The primary efficacy end point was a reduction in legs-up and exercise PCWP at 1 month. The primary safety end point was serious device- or procedure-related adverse events at 1 month. Secondary efficacy end points included HF hospitalizations, changes in exercise function and health status through 12 months, and baseline to 1-month change in resting, legs-up, and 20-W exercise PCWP.Results: A total of 90 patients (median [range] age, 71 [47-90] years; 58 female [64.4%]) were randomized at 15 centers (44 SAVM vs 46 sham). There were no differences in adverse events between groups. The primary efficacy end point did not differ between SAVM or sham (mean between-group difference in PCWP, −0.03 mm Hg; 95% CI, −2.5 to 2.5 mm Hg; P = .95). There were also no differences in the secondary efficacy end points. There was no difference in the primary safety end point between the treatment (6.8% [3 of 44]) and sham (2.2% [1 of 46]) groups (difference, 4.6%; 95% CI, −6.1% to 15.4%; P = .36). There was no difference in the incidence of orthostatic hypotension between the treatment (11.4% [5 of 44]) and sham (6.5% [3 of 46]) groups (difference, 4.9%; 95% CI, −9.2% to 18.8%; P = .48).Conclusions and Relevance: Results show that SAVM was safe and technically feasible, but it did not reduce exercise PCWP at 1 month or improve clinical outcomes at 12 months in a broad population of patients with HFpEF.Trial Registration: ClinicalTrials.gov Identifier: NCT04592445Keywords
This publication has 20 references indexed in Scilit:
- Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: Rationale, Design and Lead-in Phase Results of the REBALANCE-HF TrialJournal of Cardiac Failure, 2024
- Splanchnic Nerve Block with Botulinum Toxin for Therapy of Chronic Heart Failure – Mechanism of Action (SPONGE-HF)European Journal of Heart Failure, 2023
- Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE‐HF trial roll‐in cohortEuropean Journal of Heart Failure, 2022
- Venous Tone and Stressed Blood Volume in Heart FailureJACC, 2022
- Splanchnic Nerve Ablation for Volume Management in Heart FailureJACC: Basic To Translational Science, 2022
- Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fractionEuropean Journal of Heart Failure, 2021
- Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerationsEuropean Journal of Heart Failure, 2021
- Greater Splanchnic Nerve Stimulation in Heart Failure With Preserved Ejection FractionJACC, 2021
- Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart FailureJACC: Heart Failure, 2021
- Splanchnic Nerve Block for Chronic Heart FailureJACC: Heart Failure, 2020